Mereo BioPharma
MREO
84 hedge funds and large institutions have $205M invested in Mereo BioPharma in 2025 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 23 reducing their positions, and 16 closing their positions.
1,309% more call options, than puts
Call options by funds: $5.78M | Put options by funds: $410K
0.94% more ownership
Funds ownership: 62.11% → 63.04% (+0.94%)
0% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 23
2% less funds holding
Funds holding: 86 → 84 (-2)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
23% less capital invested
Capital invested by funds: $268M → $205M (-$62.6M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$4.72M |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$4.63M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$4.44M |
| 4 |
UBS AM
Chicago,
Illinois
|
+$3.52M |
| 5 |
BOCH
Blue Owl Capital Holdings
New York
|
+$2.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$18.2M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$2.58M |
| 3 |
Alkeon Capital Management
New York
|
-$1.84M |
| 4 |
Renaissance Technologies
New York
|
-$1.64M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$1.56M |
MREO Hedge Fund Activity: Q3 2025 in Review
84 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q3 2025, worth a combined $205M — down 23% from $268M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of MREO and 14 opened new positions — a net loss of 2 holders — while 23 trimmed existing stakes and 23 added.
The largest buyer was Morgan Stanley, adding an estimated $4.72M. The largest seller was Deerfield Management, exiting entirely with an estimated $18.2M sold.
- 84 institutional investors held Mereo BioPharma (MREO) as of Q3 2025, down from 86 in Q2 2025.
- Funds reported $205M of Mereo BioPharma stock for Q3 2025, down 23% quarter-over-quarter.
- 14 funds opened new Mereo BioPharma positions in Q3 2025 and 16 closed out, a net change of -2 holders.
- The largest Mereo BioPharma buyer in Q3 2025 was Morgan Stanley, an estimated $4.72M added.
- The largest Mereo BioPharma seller in Q3 2025 was Deerfield Management, an estimated $18.2M sold.
Based on aggregated 13F filings for Q3 2025.